Natural product-based nanoengineering in gastrointestinal stromal tumors: early promise and translational challenges Authors: Liyang Cai, Yuki Nakanishi Published: 2026 Gastrointestinal stromal tumor (GIST) remains a clinically challenging malignancy because recurrence, metastatic progression, and resistance to tyrosine kinase inhibitors (TKIs) continue to limit durable disease control (1,2). In this context, nanotechnology has emerged as a potentially useful strategy to improve therapeutic precision and complement existing targeted approaches (3). Among nanomaterials explored for oncologic applications, zinc oxide nanoparticles (ZnO NPs) have attracted increasing attention because of their intrinsic ability to induce reactive oxygen species (ROS), promote oxidative stress, and modulate apoptosis-related signaling pathways (4-6). Over the past several years, multiple ZnO-based nanocomposite platforms have been developed and evaluated across different tumor models, as summarized in Table 1. However, this literature remains dominated by non-GIST settings, particularly epithelial tumor models, with only limited mesenchymal examples such as osteosarcoma. In this context, the extension of ZnO-based strategies to GIST, as reported by Ye et al. (16), represents a conceptually interesting expansion into a less explored disease context. Accordingly, Table 1 is intended to highlight broader mechanistic and translational themes that may inform future work in GIST. At present, however, the study by Ye et al. is best interpreted as an early proof-of-concept with limited GIST specificity. Table 1Recent ZnO-based nanocomposite systems in cancer therapyCompound nameCancer typeNanoplatform compositionFunctional modalityKey mechanismZnO-ExosOsteosarcomaZnO NP-educated osteosarcoma cell-derived exosomesAnti-metastatic nanoplatformZn2⁺/HIF-1α/miR-1287-5p/Snail axis; EMT reversal and metastasis suppression (7)RR-ZnONPsOsteosarcoma (MG-63)Green-synthesized ZnO nanoparticlesPro-apoptotic nanoplatformROS/Bax/caspase-mediated mitochondrial apoptosis (8)CS-ZnO BNCsBreast cancerChitosan + ZnO NPsOvercoming radioresistanceInduction of DNA double-strand breaks, enhanced apoptotic activity, and impairment of DNA repair mechanisms (9)ZnO2@PtBreast cancerPeroxidase-mimicking platinum + ZnO2 NPsROS amplifierCatalyzes the conversion of H2O2 into hydroxyl radicals (•OH) and disrupts tumor cell energy metabolism (10)CCM-CS/ZnO@siRNABreast cancerChitosan + siRNA + ZnO NPssiRNA delivery platformDeliver encapsulated siRNA to achieve gene silencing and induces apoptosis in tumor cells (11)Au@ZnO@GQDs/HA NPsBreast cancerGold nanorods + graphene quantum dots + hyaluronic acid + ZnO NPsNanoplatform for photothermal therapyFunctions as an efficient photosensitizer, enhancing photocatalytic therapeutic efficacy by facilitating electron transfer (12)MONPsBreast cancerMn2⁺+ ZnO2-NPsSynergistic antitumor immunotherapyInduces ICD and amplifies STING-mediated innate immune activation (13)Fe-ZnO2@HABreast cancerHyaluronic acid + iron + ZnO2Remodeling of the tumor stromal microenvironmentGenerates highly oxidative hydroxyl radicals (•OH) to degrade hyaluronic acid in the tumor extracellular matrix and induce ferroptosis (14)CuxO@ZnOColorectal cancerCuxO + ZnO NPsNanoplatform for sonodynamic therapyAchieves deep tumor penetration and enhances tumor cell internalization upon ultrasound exposure (15)CuxO, copper oxide; DNA, deoxyribonucleic acid; EMT, epithelial-mesenchymal transition; HIF-1α, hypoxia-inducible factor 1 alpha; H2O2, hydrogen peroxide; ICD, immunogenic cell death; miR-1287-5p, microRNA-1287-5p; NP, nanoparticle; ROS, reactive oxygen species; siRNA, small interfering RNA; STING, stimulator of interferon genes; ZnO, zinc oxide; ZnO2, zinc peroxide; •OH, hydroxyl radical. Recent ZnO-based nanocomposite systems in cancer therapy CuxO, copper oxide; DNA, deoxyribonucleic acid; EMT, epithelial-mesenchymal transition; HIF-1α, hypoxia-inducible factor 1 alpha; H2O2, hydrogen peroxide; ICD, immunogenic cell death; miR-1287-5p, microRNA-1287-5p; NP, nanoparticle; ROS, reactive oxygen species; siRNA, small interfering RNA; STING, stimulator of interferon genes; ZnO, zinc oxide; ZnO2, zinc peroxide; •OH, hydroxyl radical. In their recent study, Ye et al. constructed a multifunctional nanocomposite, ZnO@CS-baicalein/Au NPs, by decorating gold nanoparticles onto baicalein/chitosan-modified ZnO nanoparticles (16). This hybrid design integrates a natural flavonoid with known biological activity (17), a redox-active ZnO scaffold, and gold nanoparticle stabilization within a single platform. Beyond its catalytic efficiency in synthesizing pyrano[2,3-d]pyrimidine derivatives, the nanocomposite demonstrated cytotoxic activity in ImGIST cells. Treatment with ZnO@CS-baicalein/Au NPs reduced viability in ImGIST cells, a patient-derived, SV40LT-immortalized gastric GIST model harboring a receptor tyrosine kinase (KIT) exon 11 V560del mutation, with a half maximal inhibitory concentration (IC50) of 109 µg/mL (16,18). While this demonstrates measurable antitumor activity in a molecularly relevant KIT-mutant context, the concentration required for half-maximal inhibition remains relatively high compared with clinically established targeted agents used in GIST. Moreover, reliance on a single immortalized and imatinib-sensitive model limits assessment of broader biological relevance across the heterogeneous GIST spectrum, particularly in more refractory disease settings. Further validation in additional GIST models with diverse KIT/platelet-derived growth factor receptor alpha (PDGFRA) genotypes and resistance states, together with optimization of nanoparticle formulation, intracellular uptake efficiency, and tumor selectivity, will therefore be necessary before translational relevance can be fully established. Mechanistically, Ye et al. reported that the nanocomposite suppressed phosphoinositide 3-kinase (PI3K)/protein kinase B(Akt)/mammalian target of rapamycin (mTOR) signaling (16), a pathway widely implicated in cancer progression and therapeutic resistance (19). They also observed increased Bax and P53 expression, decreased B-cell lymphoma 2 (Bcl2) and phosphorylated signal transducer and activator of transcription 3 (pSTAT3)/STAT3 levels, and S-phase accumulation. While these changes are consistent with apoptotic and cell-cycle stress responses in a GIST cell context, they do not by themselves establish meaningful interference with KIT/PDGFRA-driven GIST biology, because the study did not directly examine whether these downstream changes were linked to suppression of KIT/PDGFRA-driven signaling. At present, these findings are therefore more appropriately interpreted as preliminary mechanistic correlates of antitumor activity in GIST cells rather than definitive evidence of GIST-specific pathway targeting. Such S-phase enrichment may reflect replication stress or deoxyribonucleic acid (DNA) synthesis arrest rather than enhanced proliferation, a distinction that warrants further mechanistic clarification. From a clinical perspective, GISTs are predominantly driven by activating mutations in KIT or PDGFRA (20,21). While surgical resection remains the curative standard for localized disease, the treatment of advanced and high-risk GIST has evolved into a sequential, genotype-informed TKI paradigm (1,21,22). Imatinib is the standard first-line therapy, followed by sunitinib, regorafenib, and ripretinib in later lines, whereas avapritinib is particularly relevant in PDGFRA exon 18-mutant disease, especially D842V-mutant GISTs (1,2,21). Nevertheless, durable complete responses remain rare, and acquired resistance driven by secondary KIT/PDGFRA alterations and interlesional heterogeneity continues to limit long-term disease control (2,23). These persistent limitations provide a rationale for exploring alternative therapeutic strategies, including nanoplatform-based approaches. In this setting, nanoplatform-based strategies may hold conceptual value not as replacements for established TKIs, but as exploratory approaches that could complement current targeted therapy and help address refractory disease biology (24). Although ZnO@CS-baicalein/Au NPs modulate downstream PI3K/Akt/mTOR signaling (16), their interaction with KIT-driven oncogenic signaling and their potential capacity to overcome TKI resistance remain unexplored. Evaluation in resistant GIST models and investigation of combination strategies with established TKIs would substantially strengthen the translational relevance of this nanoplatform. The conceptual strength of this study lies in the functional coupling of natural-product pharmacology with nanoengineering. By incorporating baicalein—a natural flavonoid with reported anticancer activity and PI3K/Akt-related regulatory potential (17,25)—into a ZnO-based nanoscaffold and stabilizing it with gold nanoparticles, the authors created a multifunctional hybrid system. Such integration reflects a broader trend in nanomedicine toward platforms that combine catalytic properties with biological activity (26). Nevertheless, translational challenges remain substantial. Despite encouraging preclinical findings across various tumor types (Table 1), nanoparticle-based anticancer therapies have not consistently demonstrated clear clinical superiority in terms of efficacy or safety (27). Limitations of the enhanced permeability and retention (EPR) effect (28), tumor stromal barriers, intertumoral heterogeneity, and uncertainties in biodistribution continue to constrain therapeutic benefit. Particularly in GIST—where stromal architecture may influence drug penetration—comprehensive in vivo validation, including pharmacokinetic profiling, tumor accumulation studies, resistance modeling, and long-term safety assessment, will be indispensable. In summary, ZnO@CS-baicalein/Au NPs represent a conceptually promising but still preliminary nanoplatform for GIST, and their broader therapeutic relevance remains to be established. While the present study provides proof-of-concept evidence of in vitro antitumor activity and mechanistic modulation, future investigations will be required to bridge the gap between experimental feasibility and clinical applicability. Rigorous biological validation and rational integration with established targeted strategies will ultimately determine whether such multifunctional ZnO-based nanocomposites can contribute meaningfully to precision cancer therapy. Supplementary The article’s supplementary files as Available at https://jgo.amegroups.com/article/view/10.21037/jgo-2026-1-0179/prf